Newlink Genetics

Lumos Pharma, Inc. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO”

NewLink Genetics Stockholders Approve Merger with Lumos Pharma

Investors are looking forward to updates on NewLink's (NLNK) merger with Lumos Pharma, when the former releases fourth-quarter 2019 results.

NewLink (NLNK) to Report Q4 Earnings: What's in the Cards?

NewLink Genetics Corp. (NASDAQ: NLNK) shares jumped on Tuesday after the company announced that it entered into an exclusive worldwide license agreement with Ellipses Pharma.

Why This Ovarian Cancer Drug Could Be Huge for NewLink Genetics

AMES, Iowa, Dec.  23, 2019  (GLOBE NEWSWIRE) --  NewLink Genetics Corporation  (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses Pharma Limited (Ellipses) for the development of and rights to commercialize NLG207 (formerly CRLX101), a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin. This license agreement signed by NewLink Genetics and Ellipses is effective as of December 17, 2019. Under the terms of the agreement, Ellipses purchased NewLink’s inventory of NLG207 related materials, and NewLink will have the potential to receive future royalty payments or a share of any future economics related to NLG207.  As part of the license agreement, Ellipses also gained the rights to develop and commercialize CRLX-301, a nanoparticle formulation of docetaxel that has completed a Phase 1a study.

NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207

Merck

NewLink Genetics Corp. (NASDAQ: NLNK) and Merck & Co. Inc. (NYSE: MRK) shares made handy gains on Friday after it was announced that the U.S. Food and Drug Administration (FDA) has granted approval to Ervebo, the Zaire Ebola virus vaccine V920.

The First Ebola Vaccine Has Been Approved in the US

AMES, Iowa, Dec.  20, 2019  (GLOBE NEWSWIRE) --  NewLink Genetics Corporation  (NASDAQ:NLNK) announced today that, after priority review, the  FDA has granted approval of ERVEBO® , or Zaire Ebola virus vaccine V920 (rVSV∆G-ZEBOV-GP), as confirmed by our partner,  Merck  (NYSE:MRK), known as MSD outside the US and Canada. This represents the first vaccine approved by the FDA for the Ebola virus and follows the November 11th grant by the European Commission (EC) of a  marketing authorization for ERVEBO®  across 31 European countries. 

NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)

Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.

Do Options Traders Know Something About NewLink Genetics (NLNK) Stock We Don't?

Board Continues to Believe that Planned Lumos Merger Agreement is in the Best Interests of NewLink Stockholders Board Continues to Believe that Planned Lumos Merger Agreement is in the Best Interests of NewLink Stockholders

NewLink Genetics Responds to Proposal from Evercel

NewLink Genetics Corporation (NLNK) Management on Q3 2019 Results - Earnings Call Transcript

AMES, Iowa, Oct.  21, 2019  (GLOBE NEWSWIRE) --  NewLink Genetics Corporation  (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use  (CHMP) adopted a positive opinion recommending a conditional marketing authorization for investigational V920 Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP) , as confirmed by our partner,  Merck & Co., Inc.  (NYSE:MRK). This Committee recommendation will now be reviewed by the European Commission (EC) which, if it chooses to affirm the CHMP’s recommendation, will grant a centralized marketing authorization of the vaccine (brand name ERVEBO®) under a unified label valid in 31 European countries.

NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins, current CEO of Lumos Pharma --    -- Lumos asset, LUM-201, represents first oral therapeutic candidate for pediatric growth hormone deficiency (PGHD) with planned Phase 2b expected to begin in mid-2020 --

NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases

AMES, Iowa, Sept.  17, 2019  (GLOBE NEWSWIRE) --  NewLink Genetics Corporation  (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration (FDA)  has accepted Merck’s Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine (V920),  for the prevention of disease caused by the Ebola Zaire virus. Merck’s rolling submission was made pursuant to the FDA’s Breakthrough Therapy Designation for V920, a designation awarded to our partner, Merck, in July 2016. The Prescription Drug User Fee Act (PDUFA), or target action date, is set for March 14, 2020. As NewLink has previously stated, the FDA’s approval of this Ebola vaccine would trigger the issuance of a priority review voucher owned by Merck and in which NewLink Genetics has a substantial economic interest. Thereafter, NewLink would have the right to monetize its share of interest in the voucher. This Ebola vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC) and thereafter licensed to NewLink Genetics.

NewLink Genetics Announces FDA Accepts Partnered Biologics License Application (BLA) and Grants Priority Review for Ebola Vaccine V920 (rVSV∆G-ZEBOV-GP)

Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock?

Implied Volatility Surging for NewLink Genetics (NLNK) Stock Options

NewLink Genetics Corporation (NLNK) CEO Charles Link on Q1 2019 Results - Earnings Call Transcript

News for Newlink Genetics Stock (NLNK)